|
1
|
Mosrati MA, Malmström A, Lysiak M,
Krysztofiak A, Hallbeck M, Milos P, Hallbeck AL, Bratthäll C,
Strandéus M, Stenmark-Askmalm M and Söderkvist P: TERT promoter
mutations and polymorphisms as prognostic factors in primary
glioblastoma. Oncotarget. 6:16663–16673. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reitman ZJ, Pirozzi CJ and Yan H:
Promoting a new brain tumor mutation: TERT promoter mutations in
CNS tumors. Acta Neuropathol. 126:789–792. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Integrated genomic analysis identifies clinically relevant subtypes
of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Labussière M, Boisselier B, Mokhtari K, Di
Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O,
Paterra R, Marie Y, et al: Combined analysis of TERT, EGFR, and IDH
status defines distinct prognostic glioblastoma classes. Neurology.
83:1200–1206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nonoguchi N, Ohta T, Oh JE, Kim YH,
Kleihues P and Ohgaki H: TERT promoter mutations in primary and
secondary glioblastomas. Acta Neuropathol. 126:931–937. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:pp. 6021–6026. 2013,
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
George J, Banik NL and Ray SK: Knockdown
of hTERT and concurrent treatment with interferon-gamma inhibited
proliferation and invasion of human glioblastoma cell lines. Int J
Biochem Cell Biol. 42:1164–1173. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beck S, Jin X, Sohn YW, Kim JK, Kim SH,
Yin J, Pian X, Kim SC, Nam DH, Choi YJ and Kim H: Telomerase
activity-independent function of TERT allows glioma cells to attain
cancer stem cell characteristics by inducing EGFR expression. Mol
Cells. 31:9–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Joo KM, Kim J, Jin J, Kim M, Seol HJ,
Muradov J, Yang H, Choi YL, Park WY, Kong DS, et al:
Patient-specific orthotopic glioblastoma xenograft models
recapitulate the histopathology and biology of human glioblastomas
in situ. Cell Rep. 3:260–273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Joo KM, Kim SY, Jin X, Song SY, Kong DS,
Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, et al: Clinical and
biological implications of CD133-positive and CD133-negative cells
in glioblastomas. Lab Invest. 88:808–815. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pollard SM, Yoshikawa K, Clarke ID, Danovi
D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, et
al: Glioma stem cell lines expanded in adherent culture have
tumor-specific phenotypes and are suitable for chemical and genetic
screens. Cell Stem Cell. 4:568–580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ito M, Hiramatsu H, Kobayashi K, Suzue K,
Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, et
al: NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse
model for engraftment of human cells. Blood. 100:3175–3182. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu T, Wang N, Cao J, Sofiadis A, Dinets
A, Zedenius J, Larsson C and Xu D: The age- and shorter
telomere-dependent TERT promoter mutation in follicular thyroid
cell-derived carcinomas. Oncogene. 33:4978–4984. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oh YT, Cho HJ, Kim J, Lee JH, Rho K, Seo
YJ, Choi YS, Jung HJ, Song HS, Kong DS, et al: Translational
validation of personalized treatment strategy based on genetic
characteristics of glioblastoma. PLoS One. 9:e1033272014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Olshen AB, Venkatraman ES, Lucito R and
Wigler M: Circular binary segmentation for the analysis of
array-based DNA copy number data. Biostatistics. 5:557–572. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li H and Durbin R: Fast and accurate short
read alignment with Burrow-Wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H, Handsaker B, Wysoker A, Fennell T,
Ruan J, Homer N, Marth G, Abecasis G and Durbin R: 1000 Genome
Project Data Processing Subgroup: The sequence Alignment/Map format
and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu TD and Nacu S: Fast and SNP-tolerant
detection of complex variants and splicing in short reads.
Bioinformatics. 26:873–881. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vinagre J, Pinto V, Celestino R, Reis M,
Pópulo H, Boaventura P, Melo M, Catarino T, Lima J, Lopes JM, et
al: Telomerase promoter mutations in cancer: An emerging molecular
biomarker? Virchows Arch. 465:119–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fichtner I, Rolff J, Soong R, Hoffmann J,
Hammer S, Sommer A, Becker M and Merk J: Establishment of
patient-derived non-small cell lung cancer xenografts as models for
the identification of predictive biomarkers. Clin Cancer Res.
14:6456–6468. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
John T, Kohler D, Pintilie M, Yanagawa N,
Pham NA, Li M, Panchal D, Hui F, Meng F, Shepherd FA and Tsao MS:
The ability to form primary tumor xenografts is predictive of
increased risk of disease recurrence in early-stage non-small cell
lung cancer. Clin Cancer Res. 17:134–141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee HW, Lee JI, Lee SJ, Cho HJ, Song HJ,
Jeong DE, Seo YJ, Shin S, Joung JG, Kwon YJ, et al: Patient-derived
xenografts from non-small cell lung cancer brain metastases are
valuable translational platforms for the development of
personalized targeted therapy. Clin Cancer Res. 21:1172–1182. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hale JS, Otvos B, Sinyuk M, Alvarado AG,
Hitomi M, Stoltz K, Wu Q, Flavahan W, Levison B, Johansen ML, et
al: Cancer stem cell-specific scavenger receptor CD36 drives
glioblastoma progression. Stem Cells. 32:1746–1758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Borah A, Raveendran S, Rochani A, Maekawa
T and Kumar DS: Targeting self-renewal pathways in cancer stem
cells: Clinical implications for cancer therapy. Oncogenesis.
4:e1772015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin
L and Garraway LA: Highly recurrent TERT promoter mutations in
human melanoma. Science. 339:957–959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chiba K, Johnson JZ, Vogan JM, Wagner T,
Boyle JM and Hockemeyer D: Cancer-associated TERT promoter
mutations abrogate telomerase silencing. Elife. 4:2015. View Article : Google Scholar
|
|
29
|
Ko E, Seo HW, Jung ES, Kim BH and Jung G:
The TERT promoter SNP rs2853669 decreases E2F1 transcription factor
binding and increases mortality and recurrence risks in liver
cancer. Oncotarget. 7:684–699. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huse JT: TERT promoter mutation designates
biologically aggressive primary glioblastoma. Neuro Oncol. 17:5–6.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Simon M, Hosen I, Gousias K, Rachakonda S,
Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A and Kumar R:
TERT promoter mutations: A novel independent prognostic factor in
primary glioblastomas. Neuro Oncol. 17:45–52. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Spiegl-Kreinecker S, Lötsch D, Ghanim B,
Pirker C, Mohr T, Laaber M, Weis S, Olschowski A, Webersinke G,
Pichler J and Berger W: Prognostic quality of activating TERT
promoter mutations in glioblastoma: Interaction with the rs2853669
polymorphism and patient age at diagnosis. Neuro Oncol.
17:1231–1240. 2015. View Article : Google Scholar : PubMed/NCBI
|
